Pharmacokinetic Comparison of 2 Fixed-Dose Combination Tablets of Amlodipine and Valsartan in Healthy Male Korean Volunteers: A Randomized, Open-Label, 2-Period, Single-Dose, Crossover Study  by Kim, Yukyung et al.
Clinical Therapeutics/Volume 35, Number 7, 2013
Pharmacokinetic Comparison of 2 Fixed-Dose Combination
Tablets of Amlodipine and Valsartan in Healthy Male
Korean Volunteers: A Randomized, Open-Label, 2-Period,
Single-Dose, Crossover Study
Yukyung Kim, MD1,2; Mijeong Son, MD1,2; Donghwan Lee, MD1,2; Hyerang Roh, BS1,2;
Hankil Son, MS1,2; Dongwoo Chae, MD1,2; Mi Young Bahng, BS3; and
Kyungsoo Park, PhD, MD1,2
1Department of Pharmacology, Yonsei University College of Medicine, Seoul, Korea; 2Brain Korea 21
Project for Medical Science, Yonsei University, Seoul, Korea; and 3Department of Clinical Development,
Dong-A ST Co, Ltd, Seoul, KoreaUS citizens aged 420 years have high blood pres-
sure.1 According to a national survey conducted in
Korea in 2011, the medical cost associated with
Accepted for publication May 30, 2013.
http://dx.doi.org/10.1016/j.clinthera.2013.05.021
0149-2918 & 2013 The Authors. Published by Elsevier Inc.
Open access under CC BY-NC-ND license.  ABSTRACT
Background: Amlodipine and valsartan have differ-
ent mechanisms of action, and it is known that the
combination therapy with the 2 drugs increases treat-
ment effects compared with the monotherapy with
each drug. A ﬁxed-dose combination (FDC) drug is a
formulation including ﬁxed amounts of active drug
ingredients combined in a single dosage form that is
expected to improve medication compliance.
Objective: The goal of this study was to compare
the pharmacokinetic proﬁles of single administration of
a newly developed FDC tablet containing amlodipine
orotate 10 mg and valsartan 160 mg (test formulation)
with the conventional FDC tablet of amlodipine besy-
late 10 mg and valsartan 160 mg (reference formula-
tion) in healthy male Korean volunteers.
Methods: This was a randomized, open-label, single-
dose, 2-way crossover study. Eligible subjects were
between the ages of 20 and 50 years and within 20%
of their ideal weight. Each subject received a single dose
of the reference and the test formulations, with a 14-day
washout period between formulations. Blood samples
were collected up to 144 hours after the dose, and
pharmacokinetic parameters were determined for amlo-
dipine and valsartan. Adverse events were evaluated
based on subject interviews and physical examinations.
Results: Forty-eight of the 50 enrolled subjects
completed the study. For both amlodipine and
valsartan, the primary pharmacokinetic parameters
were included in the range for assumed bioequi-
valence, yielding 90% CI ratios of 0.9277 to 0.9903
for AUC0–last and 0.9357 to 1.0068 for Cmax in
amlodipine, and 0.9784 to 1.1817 for AUC0–last and9340.9738 to 1.2145 for Cmax in valsartan. Dizziness was
the most frequently noted adverse event, occurring in 4
subjects with the test formulation, followed by orophar-
yngeal pain occurring in 1 subject with the test
formulation and 3 subjects with the reference formula-
tion. All other adverse events occurred in o3 subjects.
Conclusions: These ﬁndings suggest that the phar-
macokinetics of the newly developed FDC tablet of
amlodipine and valsartan did not differ signiﬁcantly
from the conventional FDC tablet in these healthy
Korean male subjects. Both formulations were well
tolerated, with no serious adverse events observed.
ClinicalTrials.gov identiﬁer: NCT01823913. (Clin
Ther. 2013;35:934–940)
& 2013 The Authors. Published by Elsevier Inc.
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INTRODUCTION
Data from the National Health and Nutrition Exami-
nation Survey 2005 to 2008 reported that 430% of
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Y. Kim et al.hypertension treatment ranked highest among com-
mon diseases.2 Hypertension is known as one of the
major risk factors for coronary heart disease, the
incidence of which can be reduced through proper
management of blood pressure.3 The World Health
Organization suggests that people with systolic blood
pressure ≥140 mm Hg and/or diastolic blood pressure
≥90 mm Hg begin treatment, because even low-risk
patients with marginally elevated blood pressure are
likely to beneﬁt from proper medical intervention.4
Amlodipine*, a class of dihydropyridines, blocks
calcium inﬂux into vascular smooth muscle and
cardiac muscle, resulting in a decrease in peripheral
vascular resistance.5 Valsartan* selectively inhibits the
binding of angiotensin II to the angiotensin I receptor in
many tissues, including vascular smooth muscle and the
adrenal gland, and blocks vasoconstriction and
aldosterone-secreting effects of angiotension II, thereby
reducing blood pressure.6 Because these 2 agents have
different mechanisms of action, combination therapy
with amlodipine and valsartan can have synergistic
effects, especially in patients with poorly controlled
hypertension. According to the review article by
Frampton et al,7 combination therapy with amlo-
dipine and valsartan more effectively reduced mean
seated systolic and diastolic blood pressure than either
amlodipine or valsartan given alone. Furthermore, it
was well tolerated, displaying less frequent adverse
events (AEs) such as peripheral edema and headache
than amlodipine monotherapy. The recent study
by Karpov et al8 also reported the effectiveness of
the combination of amlodipine and valsartan in 8336
patients who were suffering from high blood pressure.
Irrespective of such evidence, however, an additional
pill to take can signiﬁcantly decrease medication
compliance. Regarding such practicality, a ﬁxed-dose
combination (FDC) tablet comprising amlodipine be-
sylate and valsartan in a single dosage form may be a
more efﬁcient treatment option than coadministration
of each drug in a separate dose. This agent is available
in different FDC formulations: 5 mg/160 mg, 10 mg/
160 mg, and 5 mg/320 mg and 10/320 mg of
amlodipine besylate and valsartan, respectively.9*Trademark: Exforges (Novartis Pharmaceuticals Co, Ltd,
Basel, Switzerland; lot number B1004; expiration date, July
2014).
*Trademark: G-0081 (Dong-A ST Co, Ltd, Seoul, Korea; lot
number 1206002; expiration date, September 2012).
July 2013Recently, a new FDC tablet including amlodipine
orotate 10 mg and valsartan 160 mg was developed.
The current study was designed to compare the phar-
macokinetic properties and tolerability of the newly
developed FDC tablet with those of the conventional
FDC tablet of amlodipine besylate 10 mg and valsar-
tan 160 mg in healthy male Korean subjects.
SUBJECTS AND METHODS
Subjects
Eligible subjects were healthy male volunteers between
the ages of 20 and 50 years and within 20% of their ideal
body weight, with no congenital abnormality or chronic
disease. Key exclusion criteria included history of hyper-
sensitivity to amlodipine or valsartan; history of cardio-
vascular, pulmonary, renal, endogenous, gastrointestinal,
hematologic, neurologic, or hemorrhagic disease; clini-
cally signiﬁcant ﬁndings on routine laboratory tests
(serology, hematology, serum chemistry, and urinalysis);
hypotension (systolic blood pressure ≤100 mm Hg or
diastolic blood pressure ≤65 mm Hg) or hypertension
(systolic blood pressure ≥150 mm Hg or diastolic blood
pressure ≥100 mm Hg); use of prescription drugs or
herbal medications within 2 weeks or use of nonpre-
scription drugs within 1 week before the study that had
the potential to interact with amlodipine or valsartan; and
use of drugs that induce or inhibit drug-metabolizing
enzymes within 1 month before the study that had the
potential to interact with study medications.
This study was approved by the institutional review
board of Yonsei University Severance Hospital (Seoul,
Korea) and performed in accordance with the Decla-
ration of Helsinki10 and Korean Good Clinical
Practice.11 All subjects gave written informed
consent before study enrollment.
Study Design
This was a randomized, open-label, single-dose,
2-way crossover study. Subjects were randomly as-
signed into 2 groups according to a computer-
generated randomization scheme (Compaq Visual For-
tran 11.1; IMSL Fortran Library, Compaq Computer
Corporation, Houston, Texas) and received the test
and the reference formulations alternatively. The refer-
ence formulation was a single dose of the FDC tablet
containing amlodipine besylate 10 mg and valsartan
160 mg and the test formulation was a single dose of
the FDC tablet containing amlodipine orotate 10 mg
and valsartan 160 mg.935
Clinical TherapeuticsThe subjects in group 1 received the reference
formulation in period 1 and the test formulation in
period 2, and those in group 2 vice versa, with a 14-day
washout period between periods 1 and 2. According to
the guidelines of the Korea Food and Drug Admin-
istration (KFDA), after an overnight fast of 10 hours,
subjects received the reference or the test formulation
orally with 240 mL of water at 8 AM.12 Subjects were
prohibited from drinking water for 2 hours after drug
administration. Standard meals containing 700 kcal
(carbohydrate, 60%; protein, 16%; and fat, 24%) were
provided for lunch and dinner to both groups at 4 and
10 hours after the dose, respectively.
Blood Sampling
Venous blood samples were collected into
K2EDTA-containing tubes by an indwelling catheter
inserted into the forearm at 0 (predose) and 0.5, 1,
1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 144, and
192 hours after the dose for the test and the reference
drugs. Blood samples up to 48 hours were collected
(6 mL each) for plasma concentration analysis of both
amlodipine and valsartan and those sampled from
72 hours to 192 hours were collected (4 mL each) for
plasma concentration analysis of amlodipine only.
Before collecting each blood sample, 1 mL of blood
was drawn from the catheter and discarded. After
each blood sample was drawn, 1 mL of normal saline
was injected into the catheter. Separated via centrifu-
gation (3500 rpm for 10 minutes) within 30 minutes
after sampling, plasma samples were transferred to
polyethylene tubes and stored at –701C until assayed.
Bioanalysis
Plasma amlodipine and valsartan concentrations were
analyzed by BioInfra Co, Ltd (Suwon, Korea) by using a
validated UPLC-MS/MS method. Plasma (100 mL) was
added to the internal standard (for amlodipine, amlo-
dipine-d4 maleic acid salt, 10 mL of 0.0200 mg/mL in
50% methanol [vol/vol]; for valsartan, valsartan-d3, 10
mL of 20.0 mg/mL in 50% methanol [vol/vol]) and was
agitated at 1500 rpm for 3 minutes and centrifuged at
4000 rpm for 1 minute; 250 mL (amlodipine) and 400
mL (valsartan) of acetonitrile were then added. After
mixing at 1500 rpm for 3 minutes, the mixture was
centrifuged at 4000 rpm for 1 minute. The supernatant
200 mL (amlodipine) and 200 mL (valsartan) of the
mixture was transferred in a 96-well round plate 1-mL
master block. After adding 0.1% (vol/vol) formic acid to936D.W. 300 mL (amlodipine) and 350 mL (valsartan), the
diluted sample was agitated at 1500 rpm for 3 minutes
and centrifuged at 4000 rpm for 1 minute.
For the sample analysis, chromatography was per-
formed by using ACQUITY UPLC Systems (Waters
Corporation, Milford, Massachusetts) with separation
on an ACQUITY UPLC BEH C18, 1.7 mm (2.1 
50 mm; Waters Corporation). The mobile phase con-
sisted of: (A) 0.1% (vol/vol) formic acid in distilled
water and (B) 0.1% (vol/vol) formic acid in acetonitrile.
The mobile phase in UPLC under gradient condition of
amlodipine was changed as follows: (A) 70% at 0.00
and 2.30 minutes; (A) 10% at 2.40 and 3.00 minutes;
and (A) 70% at 3.10 and 3.50 minutes. The mobile
phase in UPLC under isocratic condition of valsartan
was (A) 55%. The ﬂow rate was 0.5 mL/min for
amlodipine and 0.4 mL/min for valsartan, and mean
column and sample tray temperatures were set at 30
(5)1C and 15 (5)1C for both agents, respectively.
Detection and quantiﬁcation were achieved by using
XevoTQ-S MS mass spectrometer for amlodipine and
Micromass Quattro micro API mass spectrometer
(both, Waters Corporation) for valsartan with electro-
spray ionization interface in positive mode. Nitrogen
was used as the cone gas/desolvation gas. The UPLC-
MS/MS system was controlled by using MassLynx
software (version 4.1, Waters Corporation), and the
results were processed by using Microsoft Ofﬁce Excel
2007 (Microsoft Corporation, Redmond, Washington).
A linear calibration curve was established in the range
of 0.0500 to 50.0 ng/mL for amlodipine and 50.0 to
10,000 ng/mL for valsartan.
Pharmacokinetic Analysis
The plasma concentration–time proﬁles of amlodi-
pine and valsartan of each subject were analyzed
by a noncompartmental method using WinNonlin
5.3 (Pharsight Corporation, Mountain View, California).
Pharmacokinetic parameters evaluated were AUC0–last,
Cmax, AUC0–∞, Tmax, and t½ of amlodipine and
valsartan. AUC0–last was calculated by using the linear
trapezoidal rule, AUC0–∞ as AUC0–last þ (C0–last/λz),
where C0–last was the last quantiﬁable concentration
and λz the terminal elimination rate constant; and t½
as 0.693/λz. Cmax and Tmax were determined by
searching the observed data. The primary parameters
of interest were Cmax and AUC0–last of amlodipine and
valsartan. All analyses were performed by using actual
times of sampling rather than scheduled times.Volume 35 Number 7
Table I. Demographic characteristics of the
study subjects.
Characteristic
Group 1 Group 2
(n ¼ 25) (n ¼ 25)
Age, y
Mean (SD) 27.2 (6.6) 26.3 (5.4)
Range 20–45 20–41
Weight, kg
Mean (SD) 67.5 (7.9) 69.6 (7.3)
Range 53.5–85.0 55.2–83.0
Height, cm
Mean (SD) 174.2 (6.2) 174.4 (3.7)
Range 163.6–185.2 165.1–182.5
Smoking, no. (%)
Smoker 7 (28) 14 (56)
Nonsmoker 18 (72) 11 (44)
Alcohol drinking, no. (%)
Drinker 18 (72) 15 (60)
Nondrinker 7 (28) 10 (40)
Caffeine user, no. (%)
Yes 13 (52) 10 (40)
No 12 (48) 15 (60)
Group 1 ¼ received the reference formulation in period 1
and the test formulation in period 2;
Group 2 ¼ received the test formulation in period 1 and
the reference formulation in period 2.
Y. Kim et al.Tolerability Assessments
Tolerability was assessed by evaluating AEs, vital signs
(blood pressure, body temperature, and pulse rate),
laboratory tests (hematology, blood chemistry, and uri-
nalysis), 12-lead ECG examination, and physical exami-
nation. Laboratory tests and physical examination were
evaluated at baseline and at 24 and 192 hours after the
dose in each period and at follow-up visits, with blood
pressure and pulse rate being additionally evaluated at 1,
2, 4, 8, and 12 hours after drug administration. ECG
examination was performed at baseline and 192 hours
after dosing. The hematology test evaluated white blood
cell (WBC), red blood cell count, hemoglobin, hematocrit,
platelet, differential count of WBC (neutrophil, lympho-
cyte, monocyte, eosinophil, and basophil); the blood
chemistry test evaluated calcium, inorganic phosphate,
fasting glucose, blood urea nitrogen, creatinine, uric acid,
cholesterol, total protein, albumin, total bilirubin, alkaline
phosphatase, aspartate aminotransferase, alanine amino-
transferase, ɣ-glutamyl transferase, creatine kinase, lactate
dehydrogenase, triglycerides, potassium, sodium, and
chloride; and the urinalysis evaluated speciﬁc gravity,
pH, protein, glucose, ketone, red blood cell, urobilinogen,
bilirubin, nitrite, WBC, color, turbidity, sediment, and
microscopy. Based on subject interviews and physical
examinations, any unfavorable sign (including an abnor-
mal laboratory ﬁnding) or symptom, regardless of
whether it was causally related to the study medication,
was deﬁned as an AE and recorded on case-report forms.
Statistical Analysis
Assessment of comparative bioavailability was based
on 90% CIs for geometric mean ratios (test to reference
drug) for the primary pharmacokinetic parameters
(Cmax and AUC0–last) of amlodipine and valsartan.
The 2 drugs were assumed to be bioequivalent, as
deﬁned by the KFDA, if 90% CIs for the treatment
ratios of the primary parameters were within the
range of 0.8 to 1.25.12,13
RESULTS
Study Subjects
A total of 50 healthy subjects were enrolled in the
study. The sample size of 50 was obtained by the
formulation used for a standard 2 2 crossover study,14
on the assumption that type I and type II errors were
0.05 and 0.2, respectively; the dropout rate was 10%;
and the intra-individual %CV of AUC0–last and Cmax
was 32.35% according to the previous report.15 Two ofJuly 2013the 50 subjects withdrew after drug administration, 1
subject on day 3 of the ﬁrst period, and the other in the
washout period. Both subjects withdrew due to drinking
alcohol, which was not allowed during the study. Thus,
48 subjects completed the study.
All subjects who were administered the study drug
were included in the tolerability assessments, and only
subjects who completed the blood sampling as sched-
uled were included in the pharmacokinetic analysis.
Demographic characteristics of the enrolled subjects
are summarized in Table I.
Pharmacokinetics
The mean (SD) plasma concentration–time proﬁles
of amlodipine and valsartan after the test and the
reference drugs are depicted in the Figure, and
the pharmacokinetic parameters of amlodipine and
valsartan are compared between the 2 formulations in937
Clinical TherapeuticsTable II. The 90% CIs for the geometric mean ratio of
the primary parameters were all within the comparative
bioavailability range of 0.8 to 1.25 to assume
bioequivalence of amlodipine and valsartan, yielding
90% CI ratios of 0.9277 to 0.9903 and 0.9784 to
1.1817 for AUC0–last and 0.9357 to 1.0068 and 0.9738
to 1.2145 for Cmax, respectively. In addition, the 90%
CIs for the geometric mean ratios of the secondary
parameters of amlodipine and valsartan, were 0.9256 to
0.9909 and 0.9711 to 1.1670 for AUC0–∞, 0.9636 to8
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indicating that all the secondary parameters were also
included in the comparative bioequivalence range. When
tested at the signiﬁcance level of 0.05, the sequence effect
was not signiﬁcant in any of the parameters.
Tolerability
The test and the reference drugs were well tolerated in
all subjects, and no serious AEs or drug reactions24 36 48
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Table II. Pharmacokinetic comparison of amlodipine and valsartan after single-dose administration of test
and reference drugs.*
Substance
Geometric Mean Geometric Mean Ratio (Test/Reference)
Test
(n¼ 24)
Reference
(n¼ 24) % Ratio 90% CI P
Amlodipine
Cmax, ng/mL
† 5.75 5.92 0.9706 0.9357–1.0068 0.1775
AUC0–last, ng  h/mL† 245.35 255.98 0.9585 0.9277–0.9903 0.0346
AUC0–∞, ng  h/mL† 255.44 266.73 0.9577 0.9256–0.9909 0.0385
t1/2, h
† 40.40 40.96 0.9863 0.9636–1.0095 0.3240
Tmax, h
† 6.62 6.42 1.0304 0.9851–1.0777 0.2694
Valsartan
Cmax, ng/mL
† 4128.89 3796.73 1.0875 0.9738–1.2145 0.2087
AUC0–last, ng  h/mL† 27346.26 25432.01 1.0753 0.9784–1.1817 0.2032
AUC0–∞, ng  h/mL† 28859.19 27109.18 1.0646 0.9711–1.1670 0.2592
t1/2, h
† 6.61 6.56 1.0085 0.9084–1.1197 0.8925
Tmax, h
† 2.91 2.92 0.9987 0.8877–1.1236 0.9857
Test drug ¼ the fixed-dose combination tablet containing amlodipine orotate 10 mg and valsartan 160 mg (G-0081 [Dong-
A ST Co, Ltd, Seoul, Korea]); Reference drug ¼ the fixed-dose combination tablet containing amlodipine besylate 10 mg
and valsartan 160 mg (Exforges [Novartis Pharmaceuticals Co, Ltd, Basel, Switzerland]).
*Subjects who withdrew were excluded from the analysis.
†WinNonlin bioequivalence test (Pharsight Corporation, Mountain View, California).
Y. Kim et al.occurred. Dizziness was the most frequently noted AE,
occurring in 4 subjects with the test drug, followed by
oropharyngeal pain (1 with the test drug and 3 with the
reference drug). The other AEs were headache (2 with the
test drug), ocular hyperemia, fatigue, feeling abnormal,
injury associated with device, oral herpes, back pain,
nasal congestion, and neurogenic shock (each occurred in
1 subject with the reference drug), and hordeolum,
dyspepsia, toothache, neck pain, pain in extremity, cough,
and rhinorrhea (each occurred in 1 subject with the test
drug). All AEs were mild or moderate, with no serious
AEs being observed. Most of the subjects who reported to
have an AE recovered spontaneously within a few hours
or a few days of drug administration. No clinically
signiﬁcant change was found in results of physical
examinations, vital signs, laboratory tests, or ECG results
when judged by clinicians (performed unmasked because
it was an open-label study).
DISCUSSION
This study was conducted to compare the pharmaco-
kinetic proﬁles and safety of a newly developed FDCJuly 2013tablet of amlodipine orotate 10 mg and valsartan 160
mg with the conventional FDC tablet containing
amlodipine besylate 10 mg and valsartan 160 mg in
healthy Korean male subjects. Pharmacokinetic anal-
yses showed that the newly developed FDC tablet of
amlodipine and valsartan was bioequivalent to the
conventional FDC tablet of amlodipine and valsartan
in this healthy population under the studied condi-
tions, based on the KFDA’s regulatory criteria for
bioequivalence.
AEs were mild to moderate, and no serious AEs
were reported. Among the subjects who withdrew
from the study, none was for reasons considered by
the investigators to be related to the study medication.
The incidence of AEs was not signiﬁcantly different
between the 2 formulations.
As in most bioavailability and pharmacokinetic
studies, this study has a limitation because it was
conducted in a small number of healthy, young subjects
selected with very narrow inclusion and exclusion
criteria. More studies with larger number of subjects,
including patients and the elderly, are needed.939
Clinical TherapeuticsCONCLUSIONS
The newly developed FDC tablet containing amlodipine
orotate 10 mg and valsartan 160 mg did not signiﬁ-
cantly differ in pharmacokinetic proﬁles compared with
the conventional FDC tablet containing amlodipine
besylate 10 mg and valsartan 160 mg. The new FDC
formulation met the criterion of assumed bioequivalence
with the conventional FDC formulation in both amlo-
dipine and valsartan. Both drugs were well tolerated in
the study, with no serious AEs reported. These results
indicate that the new FDC formulation can be used
interchangeably with the conventional formulation.
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